In contrast, recent studies have indicated that the sodium\glucose co\transporter 2 (SGLT2) inhibitors empagliflozin, canagliflozin, and dapagliflozin have a benefit on the incidence of heart failure,4 potentially because of direct improvement of myocardial relaxation in addition to diuretic effects
In contrast, recent studies have indicated that the sodium\glucose co\transporter 2 (SGLT2) inhibitors empagliflozin, canagliflozin, and dapagliflozin have a benefit…